Novo Nordisk A/S is a well-known pharmaceutical company that has recently received a neutral recommendation from UBS. The company specializes in pharmaceutical products, with a strong focus on treatments for diabetes and obesity, which account for 92.6% of its sales.

Aside from diabetes and obesity treatments, Novo Nordisk also offers treatments for rare diseases such as hemophilia and various blood and hormonal disorders, which make up the remaining 7.4% of its sales.

In terms of geographical distribution, Novo Nordisk's sales are primarily concentrated in the United States, accounting for 54.9% of its revenue. Other significant markets include Europe, the Middle East, and Africa at 21.9%, China at 7.2%, and North America at 3.9%. The remaining 12.1% of sales are attributed to other regions.